Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Abroad (travel likely)RecruitingPHASE3
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor · Breast Cancer · Metastatic Breast Cancer · Advanced Breast Cancer
Locations
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Beverly Hills Cancer Center, Beverly Hills, California, United States
- Cedars-Sinai Medical Center, Beverly Hills, California, United States
- City of Hope, Duarte, California, United States
- Stanford University School of Medicine, Palo Alto, California, United States
- University of California Davis, Sacramento, California, United States
- University of California San Diego, San Diego, California, United States
- University of California San Francisco, San Francisco, California, United States
- Kaiser Permanente - Vallejo, Vallejo, California, United States
- Rocky Mountain Cancer Centers, Longmont, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Medical Oncology Hematology Consultants, Newark, Delaware, United States
- Medstar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Florida Cancer Specialists, Fort Myers, Florida, United States
- Cancer Care Centers of Brevard, Palm Bay, Florida, United States
- Rush Medical College, Chicago, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
- Community Health Network, Indianapolis, Indiana, United States
- University of Kansas Medical Center, Westwood, Kansas, United States
- Cancer Center of Kansas, Wichita, Kansas, United States
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Profound Research LLC, Royal Oak, Michigan, United States
- Minnesota Oncology Hematology, Minneapolis, Minnesota, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- Washington University, St Louis, Missouri, United States
- Nebraska Cancer Specialists, Omaha, Nebraska, United States
- Renown Regional Medical Center, Reno, Nevada, United States
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
- Rutgers Cancer Institute, New Brunswick, New Jersey, United States
- NYU Langone Cancer Center, New York, New York, United States
- Mount Sinai, New York, New York, United States
- Columbia University Herbert Irving Medical Center, New York, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Avera Cancer Institute, Sioux Falls, South Dakota, United States
- Tennessee Cancer Specialists, Knoxville, Tennessee, United States
- Tennessee Oncology, Nashville, Tennessee, United States
- Texas Oncology Central/South, Austin, Texas, United States
- Texas Oncology DFW, Dallas, Texas, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Houston Methodist Hospital, Houston, Texas, United States
- University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
- Baylor Scott and White Research Institute, Temple, Texas, United States
- Huntsman Cancer Center, University of Utah, Salt Lake City, Utah, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Virginia Oncology Associates, Norfolk, Virginia, United States
- University of Wisconsin, Madison, Wisconsin, United States
- St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
- Sydney Adventist Hospital, Wahroonga, New South Wales, Australia
- Barwon Health, Geelong, Victoria, Australia
- Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
- The Alfred Hospital, Melbourne, Victoria, Australia
- Sunshine Hospital, Saint Albans, Victoria, Australia
- Ballarat Oncology & Haematology Service, Wendouree, Victoria, Australia
- Medical University of Graz, Graz, Austria
- Ordensklinikum Linz GmbH, Linz, Austria
- LKH Feldkirch, Interne E am LKH Rankweil, Rankweil, Austria
- Centre Hospitalier de l'Ardenne, Libramont, Belgium
- CHU-UCL Namur, Site Sainte-Elisabeth, Namur, Belgium
- Vitaz, Campus Sint-Niklaas, Sint-Niklaas, Belgium
- CHR de Verviers site Tourelle, Verviers, Belgium
- CEON+ Pesquisas, São Caetano do Sul, São Paulo, Brazil
- Centro de Pesquisa Oncoclinica Natal Oncoclinicas, Natal, Brazil
- Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil
- Centro Gaúcho Integrado de Oncologia, Hematologia, Ensino e Pesquisa, Porto Alegre, Brazil
- Centro de Pesquisa Clínica da Associação Hospitalar Moinhos de Vento, Porto Alegre, Brazil
- Centro de Pesquisa em Oncologia - PUCRS, Porto Alegre, Brazil
- Oncoclinicas Rio de Janeiro, Rio de Janeiro, Brazil
- Instituto de Educação Pesquisa e Gestão em Saúde, Rio de Janeiro, Brazil
- NOB (Nucleo de Oncologia da Bahia), Salvador, Brazil
- William Osler Health System- Brampton Civic Hospital, Brampton, Ontario, Canada
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- Sunnybrook Research Institute, Toronto, Ontario, Canada
- Jewish General Hospital, Montreal, Quebec, Canada
- Masarykuv onkologicky ustav, Brno, Czechia
- Aalborg University Hospital, Aalborg, Denmark
- Zealand University Hospital, Næstved, Denmark
- Sygehus Sønderjylland, Sønderborg, Denmark
- Centre Leon Berard, Lyon, France
- Marienhospital Bottrop gGmbH, Bottrop, Germany
- Studienzentrale für das MVZ Eggenfelden GbR, Eggenfelden, Germany
- Praxis fuer Interdisziplinaere Onkologie und Haematologie, Freiburg im Breisgau, Germany
- Iaso Hospital, Athens, Greece
- Interbalkan Hospital of Thessaloniki, Thessaloniki, Greece
- Hong Kong United Oncology Centre, Hong Kong, Hong Kong
- Queen Mary Hospital, Hong Kong, Hong Kong
- IRCCS Candiolo, Candiolo, Italy
- AOU Ferrara, Arcispedale Sant'Anna, Cona, Italy
- Azienda Ospedaliera Universitaria Careggi, Florence, Italy
- Maastricht University Medical Center, Maastricht, Netherlands
- Radboud UMC, Nijmegen, Netherlands
- Haga Ziekenhuis, The Hague, Netherlands
- Pratia MCM Krakow, Krakow, Poland
- Curie Oncology, Singapore, Singapore
- CHA Bundang Medical Center, CHA University, Seongnam-si, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Gangnam Severance Hospital, Yonsei University Health System, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- The Catholic University, Seoul St. Mary's Hospital, Seoul, South Korea
- Korea University Guro Hospital, Seoul, South Korea
- Seoul National University Bundang Hospital, Seoul, South Korea
- Hospital Universitario de Badajoz, Badajoz, Spain
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Hospital Clinic de Barcelona, Barcelona, Spain
- Hospital San Pedro de Alcantara, Cáceres, Spain
- Hospital Universitario Juan Ramon Jimenez, Huelva, Spain
- Hospital Universitari Arnau de Vilanova, Lleida, Spain
- Hospital Beata Maria Ana/IOB Madrid, Madrid, Spain
- Clinica Universidad de Navarra, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital General Universitario Morales Meseguer, Murcia, Spain
- Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain
- Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan
- Taichung Veterans General Hospital, Taichung, Taiwan
- National Taiwan University Hospital, Taipei, Taiwan
- Taipei Veterans General Hospital, Taipei, Taiwan
- Chang Gung Memorial Hospital, Linkou, Taoyuan District, Taiwan